Annexon

Brisbane, CA · Biotechnology · 119 employees

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and

Funding history

Funding Round — $75.0M — Nov 2025
Funding Round — $130.5M — Jul 2022
Funding Round — $130.0M — Jul 2022
Funding Round — $102.0M — Jul 2020
Funding Round — $45.0M — Dec 2018

Recent signals

Nov 14, 2025: Raised $75.0M
Nov 12, 2025: SEC 8-K (1.01): On November 12, 2025, Annexon, Inc. entered into an underwriting agreement with Goldman Sachs & Co. LLC, TD Securities (USA) LLC, and Wells Fargo Securities, LLC to issue and sell 25,096,153 shares of its common stock at $2.60 per share and pre-funded warrants to purchase an additional 3,750,000 shares at $2.599 each, which reflects the offering price less the exercise price. This transaction signifies strategic financing efforts by the Company to bolster its capital reserves. The overall offering is designed to facilitate the Company’s growth plans and ongoing operational needs, leveraging an effective registration statement on Form S-3.
Jul 22, 2022: Raised $130.5M
Jul 08, 2022: Raised $130.0M
Jul 16, 2020: Raised $102.0M
Dec 19, 2018: Raised $45.0M

See plans & pricing → Track Annexon’s funding, hiring, and signals — with verified contacts — on Fundz.